Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Clinical trial Design: Comparator arms

2010 ASCO Annual Meeting

Published: 30 Jun 2010

Views: 10634

Rating:

Save

Prof David Cameron, Dr Christopher M Nutting, Dr Ruth Pettengell, Professor Jacek Jassem

Prof David Cameron chairs a round table debate on clinical trial design and comparator arms. The discussion examines issues such as the need to fast forward drug evaluation of targeted agents, how to detect unpredictable side effects of targeted compounds and how fast can combinations be evaluated.

Supported by an educational grant from Eisai Pharma Europe Ltd.

Categories:
Drug development

Related Videos

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising...

Prof Bertrand Tombal - Université Catholique de Louvain, Brussels, Belgium

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC ( Prof Bertrand Tombal - Université Catholique de Louvain, Brussels, Belgium )

Blood test may identify patients with non-small cell lung cancer subtype who...

Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy ( Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA )

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial...

Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype ( Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA )

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective...

Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC ( Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows...

Dr Yan Zhang - Sichuan University, Chengdu, China

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC ( Dr Yan Zhang - Sichuan University, Chengdu, China )

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal...

Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status ( Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain )

Using AI to identify patients at increased risk of side effects from radiation...

Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK

Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer ( Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

More from ecancer